COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

Mostrar otras versiones (1)

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both m...

Descripción completa

Detalles Bibliográficos
Autores principales: Malone, Robert W., Tisdall, Philip, Fremont-Smith, Philip, Liu, Yongfeng, Huang, Xi-Ping, White, Kris M., Miorin, Lisa, Del Olmo, Elena Moreno, Alon, Assaf, Delaforge, Elise, Hennecker, Christopher D., Wang, Guanyu, Pottel, Joshua, Smith, Nora, Hall, Julie M., Shapiro, Gideon, Mittermaier, Anthony, Kruse, Andrew C., García-Sastre, Adolfo, Roth, Bryan L., Glasspool-Malone, Jill, Ricke, Darrell O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336703/
https://www.ncbi.nlm.nih.gov/pubmed/32702719
http://dx.doi.org/10.21203/rs.3.rs-30934/v3
Descripción
Sumario:SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure. We explore several plausible avenues of activity including antiviral and host-mediated actions. We propose that the principal famotidine mechanism of action for COVID-19 involves on-target histamine receptor H(2) activity, and that development of clinical COVID-19 involves dysfunctional mast cell activation and histamine release.

Ejemplares similares